PCM
AZN icon

Pentwater Capital Management’s AstraZeneca AZN Stock Holding History

Pentwater Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-910,000
Closed -$64M – 155
2014
Q4 		$64M Sell
910,000
-840,000
-48% -$60.1M 0.46% 44
2014
Q3 		$125M Sell
1,750,000
-150,000
-8% -$11M 1.2% 24
2014
Q2 		$141M Buy
+1,900,000
New +$137M 1.5% 18

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pentwater Capital Management's AZN Position: Q3 2014 in Review

Pentwater Capital Management sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 50,256 shares — an estimated $3.68M sold.

Pentwater Capital Management first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $3.73M in Q2 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

  • Pentwater Capital Management reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
  • Pentwater Capital Management sold 50,256 AstraZeneca shares in Q3 2014, an estimated $3.68M.
  • Pentwater Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
  • Pentwater Capital Management's AstraZeneca position peaked at $3.73M in Q2 2014.
  • 402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Pentwater Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.